Brief: Inozyme Pharma Announces Dosing Of First Patient In First-In-Human Clinical Trial Of INZ-701 In Patients With ENPP1 Deficiency
15/11/2021 13:46
Nov 15 (Reuters) - Inozyme Pharma Inc INZY.O :
* INOZYME PHARMA ANNOUNCES DOSING OF FIRST PATIENT IN
FIRST-IN-HUMAN CLINICAL TRIAL OF INZ-701 IN PATIENTS WITH ENPP1
DEFICIENCY
* INOZYME PHARMA INC - EXPECTS TO PRESENT PRELIMINARY
BIOMARKER
AND SAFETY DATA IN FIRST HALF OF 2022
Source text for Eikon: ID:nGNX1fJj3d
Further company coverage: INZY.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Inozyme Pharma
See all newsBrief: Inozyme Pharma postpones 2025 annual meeting of stockholders
U.S. RESEARCH ROUNDUP-Advansix, Cognizant, Inozyme Pharma
U.S. STOCKS ON THE MOVE-Netflix, Acadia Pharma, CoreWeave
U.S. STOCKS ON THE MOVE-Inozyme Pharma, Emerson Electric, Stanley Black & Decker
Inozyme Pharma rises over 175% on $270 million buyout deal with BioMarin